Cambium Bio Overview
- Year Founded
-
2013
- Status
-
Public
- Stock Symbol
-
CMB
- Investments
-
1
- Share Price
-
$0.25
- (As of Wednesday Closing)
Cambium Bio General Information
Description
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. The company operates in the USA.
Contact Information
Website
www.cambium.bioCorporate Office
- 31 Lexington Drive
- Unit 2.06
- Bella Vista, New South Wales 2153
- Australia
Corporate Office
- 31 Lexington Drive
- Unit 2.06
- Bella Vista, New South Wales 2153
- Australia
Cambium Bio Timeline
Cambium Bio Stock Performance
As of 04-Nov-2026, Cambium Bio’s stock price is $0.25. Its current market cap is $7.38M with 29.4M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.25 | $0.28 | $0.24 - $0.42 | $7.38M | 29.4M | 8.58K |
Cambium Bio Financials Summary
As of 30-Sep-2026, Cambium Bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 9,609 | 7,840 | 2,150 | 2,529 |
| Revenue | 1 | |||
| EBITDA | (2,772) | (2,483) | (1,300) | |
| Net Income | (2,775) | (2,487) | (1,478) | |
| Total Assets | 2,590 | 2,152 | 3,776 | |
| Total Debt | 103 | 315 | 313 |
Cambium Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cambium Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cambium Bio Patents
Cambium Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-367508-S | Dual chamber dispensing device | Inactive | 29-May-2015 | ||
| AU-367509-S | Dual chamber dispensing device | Inactive | 29-May-2015 | ||
| CA-165644-S | Dual chamber dispensing device | Inactive | 29-May-2015 | ||
| US-D827813-S1 | Dual chamber dispensing device | Active | 29-May-2015 | ||
| AU-367510-S | Frangible connector for a dual chamber dispensing device | Inactive | 29-May-2015 |
Cambium Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cambium Bio Acquisitions (1)
Cambium Bio’s most recent deal was a Merger/Acquisition with Regeneus. The deal was made on 04-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Regeneus | 04-Apr-2024 | Merger/Acquisition | Biotechnology |
Cambium Bio ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Cambium Bio FAQs
-
When was Cambium Bio founded?
Cambium Bio was founded in 2013.
-
Where is Cambium Bio headquartered?
Cambium Bio is headquartered in Bella Vista, Australia.
-
What industry is Cambium Bio in?
Cambium Bio’s primary industry is Drug Discovery.
-
Is Cambium Bio a private or public company?
Cambium Bio is a Public company.
-
What is Cambium Bio’s stock symbol?
The ticker symbol for Cambium Bio is CMB.
-
What is the current stock price of Cambium Bio?
As of 04-Nov-2026 the stock price of Cambium Bio is $0.25.
-
What is the current market cap of Cambium Bio?
The current market capitalization of Cambium Bio is $7.38M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
